Seer IncSEER
About: Seer Inc is a biotechnology company. The company commercializes transformative products for researchers to unlock deep, unbiased biological information. Its product, the Proteograph Product Suite (Proteograph), will leverage its proprietary engineered nanoparticle (NP) technology to provide unbiased, deep, rapid, and large-scale access across the proteome.
Employees: 147
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
600% more call options, than puts
Call options by funds: $7K | Put options by funds: $1K
0% more funds holding in top 10
Funds holding in top 10: 1 [Q2] → 1 (+0) [Q3]
14% less capital invested
Capital invested by funds: $67M [Q2] → $57.7M (-$9.3M) [Q3]
14.38% less ownership
Funds ownership: 65.51% [Q2] → 51.13% (-14.38%) [Q3]
22% less funds holding
Funds holding: 89 [Q2] → 69 (-20) [Q3]
25% less repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 28
77% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 26
Research analyst outlook
We haven’t received any recent analyst ratings for SEER.
Financial journalist opinion
Based on 6 articles about SEER published over the past 30 days
